Accumulating clinical results suggest that major advances, such as the incorporation of DCs pulsed with WT1 and/or MUC1 peptide vaccines and standard anticancer therapies into the clinician’s therapeutic arsenal, can prolong OS and/or PFS in many patients with cancer [5]. This evidence concerns the gene WT1 and cancer.